New Treatment Options for DLBCL: Impact on Sequencing Therapeutic Choices : Episode 9

Opinion

Video

February 6, 2024

Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

Author(s):

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

EP: 1.Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

EP: 2.Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL

EP: 3.Treatment Selection in Second Line R/R DLBCL

EP: 4.Tafasitamab and Lenalidomide for R/R DLBCL

EP: 5.Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL

EP: 6.The Role of CAR T-Cell Therapy in R/R DLBCL

EP: 7.Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL

EP: 8.Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma

Now Viewing

EP: 9.Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

EP: 10.Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting

EP: 11.Bispecifics for Third Line Therapy of R/R DLBCL

EP: 12.R/R DLBCL: Safety Considerations for Bispecific Antibodies

EP: 13.Treatment Sequencing of Later Line Therapies in R/R DLBCL

EP: 14.Additional Data Updates from ASH 2023

EP: 15.Future Outlooks in the Treatment of R/R DLBCL

Related Content

Acute Myeloid Leukemia | stock.adobe.com

December 20th 2024

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital

November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

CP-CML | Image Credit: © สุพัฒตรา แสนพลี – stock.adobe.com

December 19th 2024

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

December 18th 2024

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

Orca-Q in Hematologic Malignancies | Image Credit: © Tatiana Shepeleva - stock.adobe.com

December 16th 2024

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT